Ivonescimab Injection 依沃西
Core role and approved indications 核心作用与已获批适应症
It achieves a synergistic effect of immune activation and inhibition of tumor angiogenesis by simultaneously blocking the PD-1 immune checkpoint and VEGF pro angiogenic pathway through a single molecule.
它通过一个分子同时阻断PD-1免疫检查点和VEGF促血管生成通路，实现免疫激活+抑制肿瘤血管生成的协同效果。
At present, three indications have been approved domestically, covering EGFR mutant non-small cell lung cancer resistant to EGFR-TKI, PD-L1 positive driver gene negative advanced non-small cell lung cancer as first-line treatment, and first-line advanced lung squamous cell carcinoma. Two of them have been included in the national medical insurance catalog.
目前国内已获批3项适应症，覆盖EGFR-TKI耐药的EGFR突变非鳞非小细胞肺癌、PD-L1阳性驱动基因阴性晚期非小细胞肺癌一线治疗、一线晚期肺鳞癌，其中2项已纳入国家医保目录。
More than 60 clinical studies have been conducted in multiple solid tumor areas such as biliary tract cancer and colorectal cancer, and 5 phase III trials have achieved positive results.
后续还在胆道癌、结直肠癌等多个实体瘤方向开展60余项临床研究，5项III期试验已取得阳性结果。
Common usage and security features 常规用法与安全性特点
The recommended dose is 20mg/kg, administered intravenously every 3 weeks. When combined with chemotherapy, intravenous infusion of ezetimibe should be given first, with a minimum interval of 30 minutes before administering the chemotherapy drug.
推荐剂量为20mg/kg，每3周静脉输注一次，联合化疗时需先输依沃西，间隔至少30分钟再输化疗药。
Compared to the traditional four drug combination regimen of "PD-1 monoclonal antibody+anti angiogenic monoclonal antibody+chemotherapy", it significantly reduces the incidence of adverse reactions such as anti vascular gastrointestinal perforation, severe bleeding, hypertension, proteinuria, etc.
相比传统“PD-1单抗+抗血管生成单抗+化疗”的四药联合方案，它大幅降低了抗血管相关的胃肠穿孔、严重出血、高血压、蛋白尿等不良反应的发生率。
Common grade 1-2 adverse reactions include anemia, leukopenia, hypothyroidism, mild rash, etc. The incidence of grade 3 and above serious adverse reactions is less than 50%, and there are no reports of treatment-related fatal adverse reactions.
常见1-2级不良反应为贫血、白细胞降低、甲状腺功能减退、轻度皮疹等，3级及以上严重不良反应发生率不到50%，无治疗相关致死性不良反应报告。
Key usage boundaries 关键使用边界
It belongs to strict prescription anti-tumor drugs and must be evaluated by a specialist oncologist before use. It is prohibited to purchase, adjust the dosage, or discontinue the medication on one's own.
属于严格处方抗肿瘤药物，必须由肿瘤专科医生评估后使用，禁止自行购买、调整剂量或停药。
It is contraindicated for patients with drug ingredient allergies, severe autoimmune diseases, uncontrolled severe infections, and moderate to severe liver and kidney dysfunction.
对药物成分过敏、活动性严重自身免疫病、未控制的重度感染、中重度肝肾功能不全患者禁用。
During the treatment period, regular check ups of blood routine, liver and kidney function, and thyroid function are required. If there is persistent dry cough, difficulty breathing, severe diarrhea, sudden increase in blood pressure, etc., the attending physician should be contacted immediately.
治疗期间需定期复查血常规、肝肾功能、甲状腺功能，出现持续干咳、呼吸困难、严重腹泻、血压骤升等情况要立即联系主治医生。
Comments